Abstract
Osimertinib is a first‐line or adjuvant therapy for non‐small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. However, owing to the adverse events associated with treatment, certain patients cannot maintain a daily regimen of 80 or 40 mg. In this study, we examined the efficacy of 40 mg of osimertinib administered every other day. In this single‐center, retrospective study, we evaluated patients with NSCLC harboring an EGFR mutation in whom treatment was initiated with 40 mg osimertinib every other day at our institution between May 2016 and June 2023. The major outcome was the duration of administering 40 mg osimertinib every other day. Six patients with NSCLC were evaluated. The median duration of 40 mg osimertinib intake every other day was 12.6 months. Four of the six patients weighed below 50 kg, and four experienced weight loss. Additionally, four of the six patients had severe renal impairment upon receiving 40 mg osimertinib every other day. Thus, our findings suggest the efficacy of administering 40 mg osimertinib every other day in patients with low bodyweight, weight loss, or severe renal impairment.
Keywords: epidermal growth factor receptor, non‐small cell lung cancer, weight loss
In this single‐center, retrospective study, we evaluated patients with non‐small cell lung cancer harboring an epidermal growth factor receptor mutation who were initiated on 40 mg osimertinib every other day. Six patients were evaluated. The median duration of 40 mg osimertinib intake every other day was 12.6 months. Four patients weighed below 50 kg and had severe renal impairment. Thus, this approach could be a treatment option for patients with low bodyweight or severe renal impairment.
INTRODUCTION
Epidermal growth factor receptor (EGFR) mutations are the most common mutations in non‐small cell lung cancer (NSCLC). Osimertinib is effective against EGFR mutation, especially the EGFR T790M mutation, 1 and is recommended as the first‐line therapy for EGFR‐mutated NSCLC 2 and also recommended as adjuvant therapy for completely resected stage II–IIIA EGFR‐mutated NSCLC. 3 According to the FLAURA and ADAURA trials, 2 , 3 15% and 10% of patients, respectively, cannot maintain continuous osimertinib use owing to its adverse effects. Thus, extending the duration of effective osimertinib treatment is essential to maintain activities of daily living (ADL) and prolong survival.
Cytotoxic agents can cause severe adverse events such as nausea and decreased appetite, which are associated with decreased ADL. In phase III trials, the incidence of any grade of nausea and decreased appetite attributable to cytotoxic agents was 33.8%–43.3% and 19.0%–26.0%, respectively. 4 , 5 , 6 Thus, some patients refuse treatment with cytotoxic agents because of their toxicities. The efficacy of gefitinib, a first‐generation EGFR tyrosine kinase inhibitor, administered every other day, has been demonstrated. 7 , 8 However, the efficacy of 40 mg of osimertinib administered every other day has not yet been reported.
METHODS
Study population
In this single‐center, retrospective, cohort study, we included patients who received 40 or 80 mg osimertinib for NSCLC harboring an EGFR mutation between May 2016 and June 2023 at the Kameda Medical Center. The exclusion criteria included patients not receiving 40 mg osimertinib every other day, those receiving osimertinib as adjuvant therapy, and those lacking exon 19 deletion or exon 21 L858R point mutation. The Cobas EGFR mutation test was used to detect EGFR mutations, while PD‐L1 expression was assessed using the PD‐L1 IHC 22C3 pharmDx assay. The study protocol complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Kameda Medical Center “23–032.” The requirement for written informed consent was waived owing to the study's retrospective nature, with no interventions performed on the patients.
Treatment strategy
All patients received initial osimertinib doses of 80 mg. Doses were tapered to 40 mg once daily, followed by 40 mg every other day when patients could not be reliably administered a specific dose owing to adverse events. The attending physician decided the initial dose of osimertinib and reduced it according to adverse events experienced.
Data collection
Data regarding patient age, sex, performance status, height, bodyweight, body mass index, pathology of lung cancer, TNM stage (according to the staging criteria of the American Joint Committee on Cancer, eighth edition), EGFR mutation status, total proportion of score of PD‐L1 (TPS), treatment line, blood test (to detect white blood cell and platelet counts and aspartate aminotransferase, alkaline phosphatase, creatine phosphatase, albumin, and creatinine levels), duration of osimertinib use at any dose, best response to initial treatment, and details of each adverse event were extracted from medical records. TPS was classified into three groups (high, ≥50%; low, 1–49%: negative, <1%).
The major outcome was the duration of administering 40 mg osimertinib every other day. The total duration of osimertinib administration at any dose, the progression‐free survival (PFS) for patients receiving 40 mg of osimertinib every other day, and relative dose intensity (RDI) of the whole duration of administering osimertinib were assessed. PFS was defined as the time from the initiation of osimertinib to disease progression or death from any cause. Efficacy was assessed from the computed tomography results according to the Response Evaluation Criteria in Solid Tumors version 1.1. Adverse events were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Categorical variables are shown as percentages (%), and continuous variables as medians (25–75 percentiles). The Kaplan–Meier method was used to estimate the dose duration and PFS for patients taking 40 mg osimertinib every other day and the overall duration of osimertinib administration at any dose using EZR on R commander version 1.61. This was a retrospective case study with a limited number of patients; thus, we did not use hypothetical testing.
RESULTS
Of the 151 patients receiving osimertinib at varying doses and treatment lines for NSCLC harboring EGFR mutations, six patients met the inclusion criteria (Figure 1). The median age was 79 years, and five were female. All patients' performance statuses were 0 or 1. All histological findings confirmed adenocarcinomas, and five of the six cases harbored the L858R mutation. Four of the six patients had severe renal impairment (Table 1). The median duration of 40 mg osimertinib administered every other day and median PFS were both 12.6 months (3.0–NA), the median overall duration of osimertinib treatment was 30.7 months (17.5–NA), and the median RDI was 45.1%. As of June 30, 2023, two patients received 40 mg osimertinib every other day (Table 2). Four patients ceased osimertinib treatment because of tumor progression. Four patients maintained their performance status, whereas two patients with worsened performance opted not to receive second‐line therapy. Of the six, four patients' bodyweights were below 50 kg, and four patients lost weight compared with that before taking the initial dose of osimertinib and at the start of 40 mg osimertinib administration every other day. Furthermore, five patients experienced renal impairment, and two patients' renal impairment worsened before taking 40 mg osimertinib every other day. In one patient, grade 3 platelet count decreased and creatine phosphokinase levels increased. Two patients experienced appetite loss and an acneiform rash (Table 3).
FIGURE 1.
Patient disposition in this study. NSCLC, non‐small cell lung cancer.
TABLE 1.
Patient characteristics.
| Patient characteristics | Overall population |
|---|---|
| Median age (IQR) | 79 (78–81) |
| Female, n (%) | 5 (83) |
| Smoking history n (%) | 0 (0) |
| Performance status, n (%) | |
| 0 | 3 (50) |
| 1 | 3 (50) |
| Histology, n (%) | |
| Adenocarcinoma | 6 (100) |
| EGFR mutation status, n (%) | |
| L858R | 5 (83) |
| Ex19del | 1 (17) |
| Total proportion score of PD‐L1, n (%) | |
| Low | 4 (66) |
| Negative | 2 (34) |
| Treatment line, n (%) | |
| First | 4 (66) |
| Second | 1 (17) |
| Third | 1 (17) |
| Before osimertinib treatment | |
| Body mass index (kg/m2) (IQR) | 23.2 (20.7–25.4) |
| Blood test, median (IQR) | |
| White blood cell (/μL) | 5600 (4800–6600) |
| Platelet (×104/μL) | 21.8 (14.0–22.4) |
| Aspartate aminotransferase (U/L) | 24.0 (21.5–28.0) |
| Alkaline phosphatase (U/L) | 17.0 (14.5–21.8) |
| Albumin (g/dL) | 3.8 (3.50–3.89) |
| Creatinine clearance (mL/min) | 48.5 (33.9–50.2) |
| Before osimertinib 40 mg every other day | |
| Body mass index (kg/m2) (IQR) | 21.5 (19.8–22.1) |
| Blood test, median (IQR) | |
| White blood cell (/μL) | 5500 (4400–6200) |
| Platelet (×104/μL) | 19.2 (11.8–23.4) |
| Aspartate aminotransferase (U/L) | 24.0 (22.2–29.5) |
| Alkaline phosphatase (U/L) | 18.5 (13.8–23.2) |
| Albumin (g/dL) | 3.8 (3.5–4.0) |
| Creatinine clearance (mL/min) | 34.9 (29.4–43.3) |
Abbreviation: IQR, interquartile range.
TABLE 2.
Results of this study.
| Median whole duration of osimertinib (months) (95% CI) | 30.7 (17.5–NA) |
|---|---|
| Median duration of osimertinib 40 mg every other day (months) (95% CI) | 12.6 (3.0–NA) |
| Median progression‐free survival (months) (95% CI) | 12.6 (3.0–NA) |
| Median relative dose intensity (%) (IQR) | 45.1 (40.9–50.3) |
| Number of continuations of taking osimertinib, n (%) | 2 (33.3) |
Abbreviations: CI, confidence interval; IQR, interquartile range.
TABLE 3.
Characteristics of the six patients.
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Age (year) | 79 | 82 | 81 | 76 | 77 | 79 |
| Sex | Female | Male | Female | Female | Female | Female |
| Smoking history | None | None | None | None | None | None |
| Performance status | 1 | 1 | 0 | 0 | 1 | 0 |
| Pathology | Ad | Ad | Ad | Ad | Ad | Ad |
| TNM stage (eighth) | IVA | IVB | IVA | Recurrence | IIB | IVB |
| Mutation status | L858R | L858R | Ex19del | L858R | L858R | L858R |
| TPS | Low | Low | Low | Low | Negative | Negative |
| Line | First | First | Third | Second | First | First |
| Before taking the initial dose osimertinib | ||||||
| Height (cm) | 148.2 | 158.8 | 142.0 | 146.0 | 148.0 | 137.6 |
| Bodyweight (kg) | 58.7 | 60.0 | 45.0 | 42.8 | 37.2 | 48.5 |
| Body mass index (kg/m2) | 26.8 | 24.0 | 22.3 | 20.1 | 17.0 | 25.8 |
| WBC (/μL) | 8800 | 6800 | 5200 | 3900 | 4700 | 5900 |
| Platelet (×104/μL) | 23.4 | 22.5 | 21.4 | 11.6 | 10.2 | 22.1 |
| AST (U/L) | 25 | 17 | 21 | 35 | 23 | 29 |
| ALT (U/L) | 14 | 12 | 16 | 24 | 18 | 23 |
| Albumin (g/dL) | 3.8 | 3.3 | 3.4 | 3.8 | 4.2 | 3.9 |
| Creatinine clearance (mL/min) | 62.2 | 49.3 | 50.6 | 29.3 | 47.7 | 22.1 |
| Before taking osimertinib 40 mg every other day | ||||||
| Bodyweight (kg) | 50.8 | 53.5 | 45.0 | 40.9 | 38.2 | 40.5 |
| Body mass index (kg/m2) | 23.2 | 21.4 | 22.3 | 19.2 | 17.4 | 21.6 |
| WBC (/μL) | 9400 | 6000 | 4200 | 6300 | 3300 | 5000 |
| Platelet (×104/μL) | 23.2 | 23.5 | 15.1 | 10.6 | 6.1 | 26.3 |
| AST (U/L) | 22 | 40 | 25 | 23 | 31 | 22 |
| ALT (U/L) | 11 | 40 | 24 | 16 | 21 | 13 |
| Albumin (g/dL) | 3.7 | 3.3 | 3.8 | 3.4 | 4.2 | 4.1 |
| Creatinine clearance (mL/min) | 34.1 | 35.6 | 45.9 | 24.4 | 47.4 | 27.8 |
| Best response to initial treatment | Partial response | Stable disease | Partial response | Partial response | Partial response | Stable disease |
| Caused by dose reduction | ||||||
| 80 mg osimertinib | G2 dysgeusia | G1 diarrhea | G2 appetite loss | G1 AST, ALT increased | G3 platelet count decreased | G3 CPK increased |
| 40 mg osimertinib | G2 mucositis oral | G2 appetite loss | G2 rash acneiform | G3 QT corrected interval prolonged | G2 platelet count decreased | G2 rash acneiform |
| Adverse events after dose reduction | Improved (G1) | Improved (G1) | Improved (G1) | Improved (G1) | Not changed | Improved (G1) |
| Results of this study | ||||||
| Whole duration of osimertinib (months) | 52.6 | 20.5 | 49.2 | 37.1 | 17.5 | 24.3 |
| Duration of osimertinib 40 mg every other day (months) | 16.8 | 4.8 | 41.0 | 12.9 | 12.2 | 3.0 |
| Progression‐free survival (months) | 16.8 | 4.8 | 41.0 | 12.9 | 12.2 | 3.0 |
| Relative dose intensity (%) | 48.0 | 51.1 | 30.4 | 42.2 | 40.4 | 62.7 |
| Continuation or end of taking osimertinib | Continuation | End | Continuation | End | End | End |
| Performance status when osimertinib terminated | 1 | 0 | 3 | 2 | ||
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; TPS, total proportion score of PD‐L1; WBC, white blood cell.
DISCUSSION
According to the AURA trial, 9 the objective response rate associated with 20 mg osimertinib once daily was 52%. These data showed that 40 mg osimertinib administered every other day could benefit some patients. The mean (min–max) area under the concentration‐time curve from 0 to time τ over the dosing interval at steady state (AUCτ) for 20 mg and 40 mg of osimertinib was 1965 (873–4990) and 5636 (2040–14 100) nMh, respectively, and the mean (min–max) Cmax values were 106.3 (45.4–280) nM and 305.1 (128–807) nM, respectively. This finding suggests that the AUCτ and Cmax for a dose of 20 mg is expected to be comparable to those for a dose of 40 mg for some patients. In this study, the plasma concentration of 40 mg osimertinib administered every other day might be similar to that of 40 mg osimertinib administered once daily in regular patients because the change in their bodyweight and renal function might influence the pharmacokinetic (PK) model of osimertinib. Osimertinib dose reduction has been reported as a risk to brain metastasis control. 10 Consequently, it is necessary to carefully consider the risks associated with osimertinib dose reduction. No patient had brain metastasis after taking osimertinib 40 mg every other day in this study.
Bodyweight has the largest effect on the PK model. 11 Moreover, toxicity occurs more frequently in patients with moderate renal impairment and low bodyweight, 12 and osimertinib's PK may be related to ethnicity and food. 13 Here, three of the six patients lost over 5 kg bodyweight, and four of the six patients' bodyweights were under 50 kg when they started osimertinib administration every other day. Inability of such patients to tolerate osimertinib may be attributed to their low bodyweight. 11 , 12 After the dose de‐escalation of osimertinib, the patients continued osimertinib treatment. Patients with severe renal impairments reportedly have 1.85‐ and 1.62‐fold higher exposure to osimertinib and its metabolites, respectively, than patients with normal renal function. 14 Four out of six patients had severe renal impairment when they started receiving osimertinib every other day. Here, plasma osimertinib concentrations might have been high in some patients owing to renal impairment. According to the FLAURA study, 2 interstitial lung disease, pneumonitis, and QT prolongation are the most common events leading to permanent discontinuation in the osimertinib arm. Plasma osimertinib concentration can affect the probability of rash and diarrhea. 12 In this study, patients experienced rash, diarrhea, appetite loss, and QT prolongation. However, these adverse events resolved after dose de‐escalation of osimertinib and patients could continue osimertinib treatment. Therefore, we should be careful of the osimertinib dose in a patient with low bodyweight or severe renal failure. 11
Our study had some limitations. It was retrospective in nature, and there were variations in decision‐making regarding osimertinib dose changes. Additionally, a limited number of participants were included in this study, and blood osimertinib concentrations were not determined.
In conclusion, our findings suggest the efficacy of administering 40 mg osimertinib every other day in patients with EGFR‐mutant NSCLC exhibiting low bodyweight, weight loss, or severe renal impairment, particularly when standard‐dose osimertinib is not well‐tolerated.
AUTHOR CONTRIBUTIONS
All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Ayumi Otsuki: Conceptualization. Kei Nakashima: Methodology. Ayumi Otsuki and Kentaro Tochigi: Investigation. Kei Nakashima: Formal analysis. Kentaro Tochigi: Resources. Ayumu Otsuki: Writing–original draft. Ayumi Otsuki, Naoki Inoshima, Kentaro Tochigi, Hiroyuki Ito and Kei Nakashima: Writing–review and editing. Hiroyuki Ito: Validation. Kei Nakashima: Supervision.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
ACKNOWLEDGMENTS
The authors thank Editage for providing language editing.
Otsuki A, Inoshima N, Tochigi K, Ito H, Nakashima K. Efficacy and safety of 40 mg osimertinib administered every other day for non‐small cell lung cancer harboring an epidermal growth factor receptor mutation: A single‐center retrospective cohort study. Thorac Cancer. 2024;15(7):570–574. 10.1111/1759-7714.15226
REFERENCES
- 1. Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M‐mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–1061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR‐mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. [DOI] [PubMed] [Google Scholar]
- 3. Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, et al. Overall survival with osimertinib in resected EGFR‐mutated NSCLC. N Engl J Med. 2023;389:137–147. [DOI] [PubMed] [Google Scholar]
- 4. Reck M, Rodriguez‐Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer. N Engl J Med. 2016;375:1823–1833. [DOI] [PubMed] [Google Scholar]
- 5. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first‐line treatment of PD‐L1‐selected patients with NSCLC. N Engl J Med. 2020;383:1328–1339. [DOI] [PubMed] [Google Scholar]
- 6. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Satoh H, Inoue A, Kobayashi K, Maemondo M, Oizumi S, Isobe H, et al. Low‐dose gefitinib treatment for patients with advanced non‐small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol. 2011;6:1413–1417. [DOI] [PubMed] [Google Scholar]
- 8. Iwata T, Kuwata T, Iwanami T, Uramoto H, Tanaka F. Six cases of lung adenocarcinoma successfully treated using alternate day administration of gefinitib. Jpn Lung Cancer Soc. 2013;53:25–28. [Google Scholar]
- 9. Jänne PA, Yang JCH, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor‐resistant non‐small‐cell lung cancer. N Engl J Med. 2015;372:1689–1699. [DOI] [PubMed] [Google Scholar]
- 10. Tozuka T, Noro R, Miyanaga A, Nakamichi S, Takeuchi S, Matsumoto M, et al. Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer. Cancer Med. 2023;12:17731–17739. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, et al. Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight. Cancer Sci. 2023;114:2087–2097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Brown K, Comisar C, Witjes H, Maringwa J, De Greef R, Vishwanathan K, et al. Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer. Br J Clin Pharmacol. 2017;83:1216–1226. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016;77:767–776. [DOI] [PubMed] [Google Scholar]
- 14. Vishwanathan K, Sanchez‐Simon I, Keam B, Penel N, De Miguel‐Luken M, Weilert D, et al. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. Pharmacol Res Perspect. 2020;8:e00613. [DOI] [PMC free article] [PubMed] [Google Scholar]